The drug in question, dubbed QLS‑111, has been created with Qlaris’ ATP-sensitive potassium channel modulator platform and is designed to lower intraocular pressure (IOP). The results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback